Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
MRI volumetrics
Multiple scleroris
disability-progression
glial-fibrillary-acidic-protein
natalizumab
neurofilament light
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
medline:
15
9
2023
pubmed:
2
8
2023
entrez:
2
8
2023
Statut:
ppublish
Résumé
There is a need in Relapsing-Remitting Multiple Sclerosis (RRMS) treatment for biomarkers that monitor neuroinflammation, neurodegeneration, treatment response, and disease progression despite treatment. To assess the value of serum glial fibrillary acidic protein (sGFAP) as a biomarker for clinical disease progression and brain volume measurements in natalizumab-treated RRMS patients. sGFAP and neurofilament light (sNfL) were measured in an observational cohort of natalizumab-treated RRMS patients at baseline, +3, +12, and +24 months and at the last sample follow-up (median 5.17 years). sGFAP was compared between significant clinical progressors and non-progressors and related to magnetic resonance imaging (MRI)-derived volumes of the whole brain, ventricle, thalamus, and lesion. The relationship between sGFAP and sNfL was assessed. A total of 88 patients were included, and 47.7% progressed. sGFAP levels at baseline were higher in patients with gadolinium enhancement (1.3-fold difference, sGFAP levels related to MRI markers of neuroinflammation and neurodegeneration.
Sections du résumé
BACKGROUND
There is a need in Relapsing-Remitting Multiple Sclerosis (RRMS) treatment for biomarkers that monitor neuroinflammation, neurodegeneration, treatment response, and disease progression despite treatment.
OBJECTIVE
To assess the value of serum glial fibrillary acidic protein (sGFAP) as a biomarker for clinical disease progression and brain volume measurements in natalizumab-treated RRMS patients.
METHODS
sGFAP and neurofilament light (sNfL) were measured in an observational cohort of natalizumab-treated RRMS patients at baseline, +3, +12, and +24 months and at the last sample follow-up (median 5.17 years). sGFAP was compared between significant clinical progressors and non-progressors and related to magnetic resonance imaging (MRI)-derived volumes of the whole brain, ventricle, thalamus, and lesion. The relationship between sGFAP and sNfL was assessed.
RESULTS
A total of 88 patients were included, and 47.7% progressed. sGFAP levels at baseline were higher in patients with gadolinium enhancement (1.3-fold difference,
DISCUSSION
sGFAP levels related to MRI markers of neuroinflammation and neurodegeneration.
Identifiants
pubmed: 37530045
doi: 10.1177/13524585231188625
pmc: PMC10503252
doi:
Substances chimiques
Biomarkers
0
Contrast Media
0
Gadolinium
AU0V1LM3JT
Glial Fibrillary Acidic Protein
0
Natalizumab
0
Neurofilament Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1229-1239Références
CNS Drugs. 2018 Jun;32(6):543-558
pubmed: 29926371
Mult Scler. 2022 Jan;28(1):102-110
pubmed: 33890520
Mult Scler. 2020 Feb;26(2):210-219
pubmed: 30570436
Neurosci Lett. 2017 Sep 14;657:166-170
pubmed: 28802830
Neuroimage. 2021 Jan 15;225:117471
pubmed: 33099007
Mult Scler Relat Disord. 2019 Aug;33:82-87
pubmed: 31174043
Brain Behav. 2022 May;12(5):e2573
pubmed: 35398999
Sci Rep. 2020 Jul 2;10(1):10923
pubmed: 32616916
Sci Rep. 2018 Oct 4;8(1):14798
pubmed: 30287870
AJNR Am J Neuroradiol. 2005 Feb;26(2):341-6
pubmed: 15709132
Drugs. 2022 Feb;82(3):323-334
pubmed: 35192158
J Neurol Neurosurg Psychiatry. 2021 Dec;92(12):1305-1312
pubmed: 34187866
Biomolecules. 2022 Jan 27;12(2):
pubmed: 35204724
Autoimmun Rev. 2015 Dec;14(12):1097-110
pubmed: 26226413
Brain Commun. 2021 Oct 09;3(4):fcab229
pubmed: 34755108
Neurology. 2019 Sep 24;93(13):e1299-e1311
pubmed: 31471502
Mult Scler Relat Disord. 2021 Oct;55:103170
pubmed: 34364034
Ann Clin Transl Neurol. 2020 Jun;7(6):992-1001
pubmed: 32495489
J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):660-668
pubmed: 32234967
N Engl J Med. 2006 Mar 2;354(9):899-910
pubmed: 16510744
Auto Immun Highlights. 2019 Aug 10;10(1):7
pubmed: 32257063
Ann Clin Transl Neurol. 2021 Mar;8(3):623-630
pubmed: 33534940
Neuroimage Clin. 2023;38:103354
pubmed: 36907041
Neurology. 2021 Nov 9;97(19):e1898-e1905
pubmed: 34504023
J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):263-270
pubmed: 31937580
Front Neurosci. 2022 Apr 14;16:819010
pubmed: 35495025
Neuroimage. 2016 Dec;143:235-249
pubmed: 27612647
Mult Scler. 2016 Nov;22(13):1709-1718
pubmed: 26883943
Neurology. 2018 Apr 24;90(17):789-800
pubmed: 29686117
Mult Scler. 2022 Dec;28(14):2231-2242
pubmed: 36062492
J Peripher Nerv Syst. 2018 Sep;23(3):174-177
pubmed: 29974556
Nucleic Acids Res. 2021 Jan 8;49(D1):D480-D489
pubmed: 33237286
Mult Scler. 2013 Aug;19(9):1175-81
pubmed: 23319072
Ann Clin Transl Neurol. 2020 Jan;7(1):139-143
pubmed: 31893563